Dechra Pharmaceuticals PLC (Dechra) is a holding company. The Company operates in four segments: Product Development, European Pharmaceuticals, US Pharmaceuticals and Services. European Pharmaceuticals markets and sells pharmaceuticals and specialist pet foods to the veterinary profession in Europe. It comprises Dechra Veterinary Products Europe and Dechra manufacturing. US Pharmaceuticals markets and sells a range of endocrine, ophthalmic, dermatological and equine products into North America. It includes Dechra Veterinary Products US. Services segment distributes veterinary products, including pharmaceuticals, specialist pet diets and instruments to veterinary practices within the United Kingdom. It also provides histology, pathology, haematology, chemistry and microbiology services to veterinary practices. In January 2012, Dechra acquired rights to HY-50. In May 2012, it acquired Eurovet Animal Health B.V.